Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 14/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 4/20 | 0.36 |
| ▸ | FNTB | P49356 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179325 | 1.00 | CXCR4 (0.51) | CXCR4CYP2D6FNTAFNTBKDM4E | |
| SCHEMBL13875218 | 1.00 | CXCR4 (0.51) | CXCR4CYP2D6FNTAFNTBKDM4E | |
| SCHEMBL4173699 | 1.00 | CXCR4 (0.51) | CXCR4CYP2D6FNTAFNTBKDM4E | |
| SCHEMBL13875189 | 0.86 | CXCR4 (0.41) | CXCR4CYP2D6FNTAFNTBKDM4E | |
| SCHEMBL4171448 | 0.86 | CXCR4 (0.41) | CXCR4CYP2D6FNTAFNTBKDM4E | |
| SCHEMBL4171449 | 0.86 | CXCR4 (0.41) | CXCR4CYP2D6FNTAFNTBKDM4E | |
| SCHEMBL4185850 | 0.86 | CXCR4 (0.41) | CXCR4CYP2D6FNTAFNTBKDM4E | |
| SCHEMBL13875271 | 0.81 | GPR119 (0.38) | CXCR4CYP2D6FNTAFNTB | |
| SCHEMBL4163663 | 0.81 | GPR119 (0.38) | CXCR4CYP2D6FNTAFNTB | |
| SCHEMBL4177280 | 0.81 | CXCR4 (0.47) | CXCR4CYP2D6FNTAFNTBPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | claimed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| US-20090093454-A1 | Chemical Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-04-09 | — | — | US | disclosed |
| EP-1853604-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006096444-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093454-A1 | Chemical Compounds | SLC10A1, CYP11B2, CYP4F3 | CXCR4 2681/4885CYP2D6 13/4885FNTA 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.